Abstract：
OBJECTIVE: This study aimed to assess the utility of 6 serum tumor markers in prognosis between gastric adenocarcinoma and gastric signet ring cell carcinoma (SRCC).
METHODS: A cohort of 3131 cases of gastric adenocarcinoma and 275 cases of gastric SRCC was assembled. The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125, alpha fetoprotein (AFP), carbohydrate antigen 242 (CA242), and carbohydrate antigen 724 (CA724) were measured in all cases. The study analyzed the association between the levels of these 6 tumor markers and the prognosis of gastric adenocarcinoma and SRCC.
RESULTS: The study revealed that gastric SRCC exhibited lower concentrations of CEA (P < .001) and CA19-9 (P = .002), along with reduced positive rates of CEA (P = .041), CA19-9 (P = .003), AFP (P < .001), and CA242 (P = .006), while displaying higher positive rates of CA724 (P = .024) than gastric adenocarcinoma. Nevertheless, the receiver operating characteristic curve demonstrated that serum tumor markers did not hold clinical significance in differentiating between gastric adenocarcinoma and SRCC. Survival analysis substantiated that the combined criteria of serum tumor markers stood as an independent risk factor for both gastric adenocarcinoma and SRCC. Notably, the nomogram indicated that serum tumor markers exerted a more substantial influence on the prognosis of gastric adenocarcinoma than on gastric SRCC.
CONCLUSIONS: The study concluded that the combined criteria of serum tumor markers emerge as independent risk factors for both subtypes of gastric cancer. Furthermore, this combined approach exhibited enhanced efficacy in prognosticating the outcome of gastric adenocarcinoma compared with gastric SRCC.
METHODS: A cohort of 3131 cases of gastric adenocarcinoma and 275 cases of gastric SRCC was assembled. The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125, alpha fetoprotein (AFP), carbohydrate antigen 242 (CA242), and carbohydrate antigen 724 (CA724) were measured in all cases. The study analyzed the association between the levels of these 6 tumor markers and the prognosis of gastric adenocarcinoma and SRCC.
RESULTS: The study revealed that gastric SRCC exhibited lower concentrations of CEA (P < .001) and CA19-9 (P = .002), along with reduced positive rates of CEA (P = .041), CA19-9 (P = .003), AFP (P < .001), and CA242 (P = .006), while displaying higher positive rates of CA724 (P = .024) than gastric adenocarcinoma. Nevertheless, the receiver operating characteristic curve demonstrated that serum tumor markers did not hold clinical significance in differentiating between gastric adenocarcinoma and SRCC. Survival analysis substantiated that the combined criteria of serum tumor markers stood as an independent risk factor for both gastric adenocarcinoma and SRCC. Notably, the nomogram indicated that serum tumor markers exerted a more substantial influence on the prognosis of gastric adenocarcinoma than on gastric SRCC.
CONCLUSIONS: The study concluded that the combined criteria of serum tumor markers emerge as independent risk factors for both subtypes of gastric cancer. Furthermore, this combined approach exhibited enhanced efficacy in prognosticating the outcome of gastric adenocarcinoma compared with gastric SRCC.
摘要：
目的：本研究旨在评估6种血清肿瘤标志物在胃腺癌和胃印戒细胞癌（SRCC）预后中的应用价值。
方法：收集3131例胃腺癌和275例胃SRCC患者的队列。血清癌胚抗原(CEA)水平,糖类抗原19-9(CA19-9),碳水化合物抗原125，甲胎蛋白（AFP），糖类抗原242(CA242),和碳水化合物抗原724（CA724）在所有情况下进行测量。该研究分析了这6种肿瘤标志物水平与胃腺癌和SRCC预后之间的关系。
结果：研究表明，胃SRCC表现出较低浓度的CEA（P<.001）和CA19-9（P=.002），随着CEA阳性率的降低(P=.041)，CA19-9（P=.003），AFP（P<.001），和CA242（P=.006），CA724阳性率高于胃腺癌（P=0.024）。然而，受试者工作特征曲线显示血清肿瘤标志物对胃腺癌和SRCC的鉴别无临床意义。生存分析证实，血清肿瘤标志物的组合标准是胃腺癌和SRCC的独立危险因素。值得注意的是,列线图显示，血清肿瘤标志物对胃腺癌预后的影响大于对胃SRCC的影响。
结论：该研究得出结论，血清肿瘤标志物的综合标准是胃癌两种亚型的独立危险因素。此外，与胃SRCC相比,这种联合方法在预测胃腺癌结局方面显示出更高的疗效.
方法：收集3131例胃腺癌和275例胃SRCC患者的队列。血清癌胚抗原(CEA)水平,糖类抗原19-9(CA19-9),碳水化合物抗原125，甲胎蛋白（AFP），糖类抗原242(CA242),和碳水化合物抗原724（CA724）在所有情况下进行测量。该研究分析了这6种肿瘤标志物水平与胃腺癌和SRCC预后之间的关系。
结果：研究表明，胃SRCC表现出较低浓度的CEA（P<.001）和CA19-9（P=.002），随着CEA阳性率的降低(P=.041)，CA19-9（P=.003），AFP（P<.001），和CA242（P=.006），CA724阳性率高于胃腺癌（P=0.024）。然而，受试者工作特征曲线显示血清肿瘤标志物对胃腺癌和SRCC的鉴别无临床意义。生存分析证实，血清肿瘤标志物的组合标准是胃腺癌和SRCC的独立危险因素。值得注意的是,列线图显示，血清肿瘤标志物对胃腺癌预后的影响大于对胃SRCC的影响。
结论：该研究得出结论，血清肿瘤标志物的综合标准是胃癌两种亚型的独立危险因素。此外，与胃SRCC相比,这种联合方法在预测胃腺癌结局方面显示出更高的疗效.
